{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:59:31Z","timestamp":1790834371331,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T00:00:00Z","timestamp":1484179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/leu.2017.8","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T07:43:01Z","timestamp":1484120581000},"page":"2151-2160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor"],"prefix":"10.1038","volume":"31","author":[{"given":"K H","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K G","family":"Pinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K-W","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-2362","authenticated-orcid":false,"given":"A","family":"Jares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Firor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Golightly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Senzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E L","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,12]]},"reference":[{"key":"BFleu20178_CR1","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K . Peripheral T-cell lymphoma. Blood 2011; 117: 6756\u20136767.","journal-title":"Blood"},{"key":"BFleu20178_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1535370215584936","volume":"240","author":"AE Firor","year":"2015","unstructured":"Firor AE, Jares A, Ma Y . From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood) 2015; 240: 1087\u20131098.","journal-title":"Exp Biol Med (Maywood)"},{"key":"BFleu20178_CR3","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra138.","journal-title":"Sci Transl Med"},{"issue":"18 Pt 1","key":"BFleu20178_CR4","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13 (18 Pt 1): 5426\u20135435.","journal-title":"Clin Cancer Res"},{"key":"BFleu20178_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","volume":"10","author":"S Arai","year":"2008","unstructured":"Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10: 625\u2013632.","journal-title":"Cytotherapy"},{"key":"BFleu20178_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/leu.2015.311","volume":"30","author":"K Pinz","year":"2016","unstructured":"Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW et al. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia 2016; 30: 701\u2013707.","journal-title":"Leukemia"},{"key":"BFleu20178_CR7","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3109\/10428194.2012.676175","volume":"53","author":"J Godfrey","year":"2012","unstructured":"Godfrey J, Benson DM Jr. . The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma 2012; 53: 1666\u20131676.","journal-title":"Leuk Lymphoma"},{"key":"BFleu20178_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med 2016; 20: 1287\u20131294.","journal-title":"J Cell Mol Med"},{"key":"BFleu20178_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014; 28: 917\u2013927.","journal-title":"Leukemia"},{"key":"BFleu20178_CR10","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","volume":"7","author":"KH Chen","year":"2016","unstructured":"Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget 2016; 7: 56219\u201356232.","journal-title":"Oncotarget"},{"key":"BFleu20178_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fphar.2015.00021","volume":"6","author":"W Glienke","year":"2015","unstructured":"Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 2015; 6: 21.","journal-title":"Front Pharmacol"},{"key":"BFleu20178_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F . Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front Immunol 2016; 7: 91.","journal-title":"Front Immunol"},{"key":"BFleu20178_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","volume":"65","author":"G Suck","year":"2016","unstructured":"Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG et al. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother 2016; 65: 485\u2013492.","journal-title":"Cancer Immunol Immunother"},{"key":"BFleu20178_CR14","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013; 15: 1563\u20131570.","journal-title":"Cytotherapy"},{"key":"BFleu20178_CR15","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia 2010; 24: 1160\u20131170.","journal-title":"Leukemia"},{"key":"BFleu20178_CR16","doi-asserted-by":"publisher","first-page":"14053","DOI":"10.1038\/mtm.2014.53","volume":"1","author":"C Wu","year":"2014","unstructured":"Wu C, Hong SG, Winkler T, Spencer DM, Jares A, Ichwan B et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies. Mol Ther Methods Clin Dev 2014; 1: 14053.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"BFleu20178_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","volume":"23","author":"K Schonfeld","year":"2015","unstructured":"Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor. Mol Ther 2015; 23: 330\u2013338.","journal-title":"Mol Ther"},{"key":"BFleu20178_CR18","doi-asserted-by":"publisher","first-page":"djv375","DOI":"10.1093\/jnci\/djv375","volume":"108","author":"C Zhang","year":"2016","unstructured":"Zhang C, Burger MC, Jennewein L, Genssler S, Schonfeld K, Zeiner P et al. ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst 2016; 108: djv375.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu20178_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","volume":"33","author":"L Boissel","year":"2009","unstructured":"Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H . Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009; 33: 1255\u20131259.","journal-title":"Leuk Res"},{"key":"BFleu20178_CR20","doi-asserted-by":"publisher","first-page":"e26527","DOI":"10.4161\/onci.26527","volume":"2","author":"L Boissel","year":"2013","unstructured":"Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2: e26527.","journal-title":"Oncoimmunology"},{"key":"BFleu20178_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","volume":"8","author":"H Jiang","year":"2014","unstructured":"Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 2014; 8: 297\u2013310.","journal-title":"Mol Oncol"},{"key":"BFleu20178_CR22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V82.2.343.343","volume":"82","author":"CH Pui","year":"1993","unstructured":"Pui CH, Behm FG, Crist WM . Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343\u2013362.","journal-title":"Blood"},{"key":"BFleu20178_CR23","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","volume":"77","author":"D Campana","year":"1991","unstructured":"Campana D, van Dongen JJ, Mehta A, Coustan-Smith E, Wolvers-Tettero IL, Ganeshaguru K et al. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 1991; 77: 1546\u20131554.","journal-title":"Blood"},{"key":"BFleu20178_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/art.1780360508","volume":"36","author":"V Strand","year":"1993","unstructured":"Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 plus rheumatoid arthritis investigators group. Arthritis Rheum 1993; 36: 620\u2013630.","journal-title":"Arthritis Rheum"},{"key":"BFleu20178_CR25","first-page":"3328","volume":"49","author":"S Siena","year":"1989","unstructured":"Siena S, Bregni M, Formosa A, Brando B, Marenco P, Lappi DA et al. Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans. Cancer Res 1989; 49: 3328\u20133332.","journal-title":"Cancer Res"},{"key":"BFleu20178_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.1780350721","volume":"35","author":"MC Wacholtz","year":"1992","unstructured":"Wacholtz MC, Lipsky PE . Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain. Arthritis Rheum 1992; 35: 837\u2013839.","journal-title":"Arthritis Rheum"},{"key":"BFleu20178_CR27","first-page":"596","volume":"21","author":"DM Fishwild","year":"1994","unstructured":"Fishwild DM, Strand V . Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function. J Rheumatol 1994; 21: 596\u2013604.","journal-title":"J Rheumatol"},{"key":"BFleu20178_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Rosenberg SA . Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267\u2013276.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu20178_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK . A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 2015; 126: 983\u2013992.","journal-title":"Blood"},{"key":"BFleu20178_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1089\/15258160152509145","volume":"10","author":"T Tonn","year":"2001","unstructured":"Tonn T, Becker S, Esser R, Schwabe D, Seifried E . Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535\u2013544.","journal-title":"J Hematother Stem Cell Res"},{"key":"BFleu20178_CR31","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.V78.8.2139.2139","volume":"78","author":"JH Antin","year":"1991","unstructured":"Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139\u20132149.","journal-title":"Blood"},{"key":"BFleu20178_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1089\/hum.2013.075","volume":"24","author":"DM Barrett","year":"2013","unstructured":"Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y . Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013; 24: 717\u2013727.","journal-title":"Hum Gene Ther"},{"key":"BFleu20178_CR33","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann H . Are natural killer cells superior CAR drivers? Oncoimmunology 2014; 3: e28147.","journal-title":"Oncoimmunology"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu20178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu20178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu20178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:11:27Z","timestamp":1684433487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu20178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,12]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFleu20178"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,12]]},"assertion":[{"value":"21 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yupo Ma is a co-founder of iCell Gene Therapeutics, LLC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}